Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Tiddlers aim to take the needle out of hospital life

Article Abstract:

Needlestick injuries represent a serious problem for healthcare workers, and a number of companies are offering solutions. Medisys has developed NicSafe, a needle incinerator, in 25 countries. A portable version of this product has been approved for sale in the US. NMT has developed a syringe with a retractable needle which has been approved in Europe and is likely to be approved in the US. Powderject and Weston Medical have developed syringes that do not use needles, for administering injections.

Author: Court, Mark
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
Hypodermic Syringes & Related Eqp, Product development, Powderject Pharmaceuticals PLC, Medisys (UK?), NMT Corp., Weston Medical

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Biotech passes its screen test

Article Abstract:

Celsis International is reporting a profit following a period of losses. Staffing and other costs have been cut, as has investment in research and development. The company has also improved the quality of its partner and client base, which includes major healthcare and pharmaceutical companies. The company could attract a bid, and Biotrace is one possible bidder. Celsis is ranked as the 13th United Kingdom biotech company in terms of growth by Deloitte and Touche.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
Testing and measuring equipment industry, Celsis International PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Electrophoretics: testing times

Article Abstract:

Electrophoretics International is a UK company which develops diagnostic tests. The company has a back-pain test with potential, and saw a rise in its share price with speculation that it could have a test for bovine spongiform encephalopathy. The company will need further funds and approval for the back-pain test is likely to take from two to three years. The company's shares are a high-risk investment, and the share price is high enough in April 1996.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
Electrophoretics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Medical equipment and supplies industry, Medical equipment industry, Management, Medical testing products
Similar abstracts:
  • Abstracts: Forget the feel-good, we want dosh. Steady as she goes
  • Abstracts: A note on the temporal variability of Canadian financial services stock returns. The role of personal wealth in small business finance
  • Abstracts: Losing faith in crystal balls. The presuppositions of Gordon Brown
  • Abstracts: National financial markets. Salient features of international market developments in 1996
  • Abstracts: A dirge too soon. Separating the wheat from the chaff. Commodities: cycling up?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.